Early health technology assessment (eHTA) approaches focused on human stem cell-related technologies: a scoping review protocol
GIST
Introduction The growing advancement of innovative stem cell technologies requires careful evaluation of their economic, clinical and societal impacts. Early economic evaluations are essential for developing new medical technologies and supporting key decisions about commercialisation and market access.
This scoping review explores Early Health Technology Assessment (eHTA) approaches specifically related to human stem cell technologies. By examining how eHTA can support the commercialisation of these therapies, we aim to clarify its role in optimising resource allocation and enhancing both the clinical and societal benefits of stem cell technologies.
Methods and analysis To explore the use of eHTA in the development of stem cell-related technologies, a scoping review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses - Scoping Review Extension guidelines. Systematic searches were conducted across scientific databases (MEDLINE, International HTA database, EconLit, PAIS Index and EconPapers), grey literature sources (Overton) and through hand-searching to identify eligible articles published from inception to 14 April 2026.
No limits were imposed on language. Reviewers will independently record data from eligible studies using a standard data abstraction form.
Clinical Editorial
Summary
BMJ Open published a clinical update in Research Highlights on 04 Jun 2026.
The item focuses on Early health technology assessment (eHTA) approaches focused on human stem cell-related technologies: a scoping review protocol.
Review the original article for the full source wording and details.